%20with%20PHO.jpg/:/rs=h:200,cg:true,m/qt=q:95)
%20with%20PHO.jpg/:/rs=h:104,cg:true,m/qt=q:95)
Depo-Provera
Links to Brain Tumors
Legal actions are forming against Pfizer, the manufacturer of Depo-Provera, alleging that prolonged use of the contraceptive injection is linked to the development of intracranial meningiomas, a type of brain tumor.
Cohen Hirsch, LP is a leading expert in handling of these types of cases.
Frightening Research
The legal actions are largely based on recent studies that have identified a significant association between Depo-Provera and an increased risk of meningiomas. A study published in The BMJ in March 2024 found that women injected with medroxyprogesterone acetate, the active ingredient in Depo-Provera, had a 5 to 6-fold higher risk of developing a meningioma. This risk increased with one year or more of use. These findings have prompted further investigations and legal scrutiny regarding the safety of the contraceptive.
These lawsuits are part of a growing number of cases filed across the United States. The plaintiffs allege that Pfizer failed to adequately warn users about the potential risks associated with prolonged use of Depo-Provera. In response to the increasing number of cases, these lawsuits have been centralized into a Multidistrict Litigation (MDL), aiming to streamline the legal process and handle the claims more efficiently.
Pfizer's Response
Pfizer has responded to these allegations by stating that Depo-Provera has been an FDA-approved medication for more than 30 years and has been a safe and effective treatment option for millions of patients during that time. The company has expressed its intent to vigorously defend against these lawsuits. However, the growing body of research linking Depo-Provera to an increased risk of meningiomas, along with the rising number of legal claims, has raised significant concerns about the safety of the contraceptive and the adequacy of the warnings provided to users.